



Stakeholder Summary

Dr Jane Tiller

June 2026



- Ethical, Legal and Social Adviser in Public Health Genomics, Monash University
- Co-lead, DNA Screen
- Technical member, Genomics Australia Advisory Council

Contact: Jane.Tiller@monash.edu; 0413 741 187

Key priorities

- Integration of genomics into public healthcare
- Advancing towards population-level DNA screening for disease prevention in adults
- Addressing legal and ethical barriers to public participation in genomic screening – most prominently, the issue of genetic discrimination in life insurance

Strategic goal

To move towards a population screening program for genomics in Australian adults, including expansion of the DNA Screen program in collaboration with the Minister's office and the Department of Health.

What is DNA Screen?

DNA Screen (<https://dnascreen.monash.edu>) is a national program of preventive genomic screening. In its pilot phase, we tested 10,000 Australians for genetic risk of developing certain cancers and heart disease, finding approximately 2% (1 in 50) at high genetic risk.

We also conducted health economic modelling, demonstrating cost-effectiveness of offering preventive genomic screening to the whole young adult population (18–40) in Australia.

We are now seeking further Australian Government investment to scale up testing to more Australians to save lives, reduce healthcare system costs, and increase productivity.

Status of matters to date

- DNA Screen pilot study completed
www.nature.com/articles/s44360-025-00020-x



- Cost-effectiveness study completed
[www.thelancet.com/journals/eclinm/article/PIIS2589-5370\(23\)00474-1](http://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00474-1)



- Key stakeholder in achieving the legislated ban on genetic discrimination in life insurance
www.nature.com/articles/s41591-026-04372-z



- Ongoing engagement with the Minister's office and Department of Health, Disability and Ageing to progress genomic screening policy

